Literature DB >> 15280666

Ubiquitination of PCNA and the polymerase switch in human cells.

Patricia L Kannouche1, Alan R Lehmann.   

Abstract

Replicative DNA polymerases are blocked by damage in the template DNA. To get past this damage, the cell employs specialized translesion synthesis (TLS) polymerases, which have reduced stringency and are able to bypass different lesions. For example, DNA polymerase eta (poleta) is able to carry out TLS past UV-induced cyclobutane pyrimidine dimers. How does the cell bring about the switch from replicative to TLS polymerase? We have shown that, in human cells, when the replication machinery is blocked at DNA damage, PCNA, the sliding clamp required for DNA replication, is mono-ubiquitinated and that this modified form of PCNA has increased affinity for poleta. This provides a mechanism for the polymerase switch. In this Extra-View, we discuss the possible signals that might trigger ubiquitination of PCNA, whether PCNA becomes de-ubiquitinated after TLS has been accomplished and the role of the hREV1 protein in TLS. We point out some apparent differences between mechanisms in Saccharomyces cerevisiae and human cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280666

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  64 in total

1.  Epstein-Barr virus BPLF1 deubiquitinates PCNA and attenuates polymerase η recruitment to DNA damage sites.

Authors:  Christopher B Whitehurst; Cyrus Vaziri; Julia Shackelford; Joseph S Pagano
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

2.  Targeting the FANCJ-BRCA1 interaction promotes a switch from recombination to poleta-dependent bypass.

Authors:  J Xie; R Litman; S Wang; M Peng; S Guillemette; T Rooney; S B Cantor
Journal:  Oncogene       Date:  2010-02-22       Impact factor: 9.867

Review 3.  The fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases.

Authors:  Scott D McCulloch; Thomas A Kunkel
Journal:  Cell Res       Date:  2008-01       Impact factor: 25.617

Review 4.  Eukaryotic translesion polymerases and their roles and regulation in DNA damage tolerance.

Authors:  Lauren S Waters; Brenda K Minesinger; Mary Ellen Wiltrout; Sanjay D'Souza; Rachel V Woodruff; Graham C Walker
Journal:  Microbiol Mol Biol Rev       Date:  2009-03       Impact factor: 11.056

Review 5.  Y-family DNA polymerases in mammalian cells.

Authors:  Caixia Guo; J Nicole Kosarek-Stancel; Tie-Shan Tang; Errol C Friedberg
Journal:  Cell Mol Life Sci       Date:  2009-04-15       Impact factor: 9.261

6.  The E3 ubiquitin ligase RAD18 regulates ubiquitylation and chromatin loading of FANCD2 and FANCI.

Authors:  Stacy A Williams; Simonne Longerich; Patrick Sung; Cyrus Vaziri; Gary M Kupfer
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

7.  PIDD orchestrates translesion DNA synthesis in response to UV irradiation.

Authors:  E Logette; S Schuepbach-Mallepell; M J Eckert; X H Leo; B Jaccard; C Manzl; A Tardivel; A Villunger; M Quadroni; O Gaide; J Tschopp
Journal:  Cell Death Differ       Date:  2011-03-18       Impact factor: 15.828

Review 8.  Global signatures of protein and mRNA expression levels.

Authors:  Raquel de Sousa Abreu; Luiz O Penalva; Edward M Marcotte; Christine Vogel
Journal:  Mol Biosyst       Date:  2009-10-01

9.  A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer.

Authors:  Shanna J Smith; Long Gu; Elizabeth A Phipps; Lacey E Dobrolecki; Karla S Mabrey; Pattie Gulley; Kelsey L Dillehay; Zhongyun Dong; Gregg B Fields; Yun-Ru Chen; David Ann; Robert J Hickey; Linda H Malkas
Journal:  Mol Pharmacol       Date:  2014-12-05       Impact factor: 4.436

10.  Proliferating cell nuclear antigen (PCNA)-binding protein C1orf124 is a regulator of translesion synthesis.

Authors:  Gargi Ghosal; Justin Wai-Chung Leung; Binoj C Nair; Ka-Wing Fong; Junjie Chen
Journal:  J Biol Chem       Date:  2012-08-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.